Biotech | May 16, 2022
Inmagene receives USFDA IND clearance for a third-generation BTK inhibitor
It is developing the drug candidate to potentially treat immunological diseases
It is developing the drug candidate to potentially treat immunological diseases
The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
The purpose of the study is to investigate safety and tolerability of SNIPR001 in healthy volunteers and to evaluate the effect of SNIPR001 on reducing E. coli colonization in the gut
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Further demonstrates Honeywell's commitment to greenhouse gas reduction and support of customers' sustainability goals through innovative new products
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
Subscribe To Our Newsletter & Stay Updated
